MESOBLAST LIMITED - Charts / Financials

2.52%

$2.32

Market Cap $2.969B

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Recce Pharmaceuticals (ASX:RCE) eyes US Defence grants with early data for R327 on burn wounds

REFRESH

Day
Open	$2.34		Day High	$2.40		Day Low	$2.30
Daily Volume	3111024

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	$2.31	8		2	$2.32	17482

Directors & Senior Management

Dr. Silviu Itescu	Chief Executive Officer, Executive Director
Mr. William M. Burns	Non-Executive Independent Vice Chairman of the Board
Mr. Andrew Chaponnel	Interim Chief Financial Officer
Dr. Fiona See	Senior Vice President, Head - Translational Research
Mr. Peter Howard	General Counsel, Corporate Executive
Dr. Eric A. Rose	Executive Director, Chief Medical Officer
Mr. Justin Horst	Head - Manufacturing
Mr. Michael Schuster	Pharma Partnering
Ms. Geraldine Storton	Head - Regulatory Affairs and Quality Management
Mr. Paul Hughes	Joint Company Secretary
Mrs. Jane Bell	Non-Executive Independent Chairman of the Board
Dr. Gregory George	Director
Ms. Lyn Cobley	Non-Executive Independent Director
Mr. Philip J. Facchina	Non-Executive Independent Director
Mr. Philip R. Krause	Non-Executive Independent Director

Data source: Refinitiv

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.32		Change -0.060(2.52%)		Mkt cap ! $2.969B

Open	High	Low	Value	Volume
$2.34	$2.40	$2.30	$7.243M	3.111M

Buyers (Bids)

No.	Vol.	Price($)
1	8	$2.31

Sellers (Offers)

Price($)	Vol.	No.
$2.32	17482	2

View Market Depth

No.	Vol.	Price($)
1	8	2.310
3	33917	2.300
9	69850	2.290
10	37461	2.280
2	7000	2.270

Price($)	Vol.	No.
2.320	17482	2
2.330	11000	2
2.340	29896	4
2.350	67873	4
2.360	20000	2

Last trade - 16.10pm 20/08/2025 (20 minute delay)

MSB (ASX) Chart

MESOBLAST LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories